Helen Kim

Helen Kim

Auto-generated profile, based on publicly available information

Helen Kim

Department of Anesthesia and Perioperative Care, Center for Cerebrovascular Research University of California San Francisco San Francisco CA USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
HSHunt All-In Stroke
Hunt All-In Stroke
MBMark K. Bakker
Mark K. Bakker
CGChina Kadoorie Biobank Collaborative Group
China Kadoorie Biobank Collaborative Group
BCBioBank Japan Project Consortium
BioBank Japan Project Consortium
TGThe ICAN Study Group
The ICAN Study Group
YRYnte Ruigrok
Ynte Ruigrok

4 March 2022 in Science
Verified
Journal Article
Closed access
EWEthan A. Winkler
Ethan A. Winkler
CKChang N. Kim
Chang N. Kim
JRJayden M. Ross
Jayden M. Ross
JGJoseph H. Garcia
Joseph H. Garcia
EGEugene Gil
Eugene Gil
TNTomasz Jan Nowakowski
Tomasz Jan Nowakowski
Cerebrovascular diseases are a leading cause of death and neurologic disability. Further understanding of disease mechanisms and therapeutic strategies requires a deeper knowledge of cerebrovascular cells in humans. We profiled transcriptomes of 181,388 cells to define a cell atlas of the adult human cerebrovasculature, including endothelial cell molecular signatures with arteriovenous segmentation and expanded perivascular cell diversity. By leveraging this reference, we investigated cellular and molecular perturbations in brain arteriovenous malformations, which are a leading cause of stroke in young people, and identified pathologic endothelial transformations with abnormal vascular patterning and the ontology of vascularly derived inflammation. We illustrate the interplay between vascular and immune cells that contributes to brain hemorrhage and catalog opportunities for targeting angiogenic and inflammatory programs in vascular malformations.

1 December 2004 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
HKHelen Kim
Helen Kim
PHPatti Hall
Patti Hall
MSMichelle Smith
Michelle Smith
MKMarion Kirk
Marion Kirk
JPJeevan K. Prasain
Jeevan K. Prasain
CGClinton Grubbs
Clinton Grubbs
Many popular dietary supplements are enriched in polyphenols such as the soy isoflavones, tea catechins, and resveratrol (from grape skins), each of which has been shown to have chemopreventive activity in cellular models of cancer. The proanthocyanidins, which are oligomers of the catechins, are enriched in grape seeds and form the basis of the dietary supplement grape seed extract (GSE). Evidence suggests that the proanthocyanidins may be metabolized to the monomeric catechins. This study was carried out to determine whether GSE added to rodent diets protected against carcinogen-induced mammary tumorigenesis in rats and whether this was affected by the composition of the whole diet. Female rats were begun on 5%, 1.25%, or 0% (control) GSE-supplemented diets at age 35 d. At age 50 d they were administered 7,12-dimethylbenz[a]anthracene (DMBA) in sesame oil at 80 mg/kg body weight. They were weighed and monitored weekly for tumor development until 120 d after DMBA administration. Administration of GSE in AIN-76A diet did not show any protective activity of GSE against DMBA-induced breast cancer. However, administration of GSE in a laboratory dry food diet (Teklad 4% rodent diet) resulted in a 50% reduction in tumor multiplicity. In similar experiments, genistein administered in AIN-76A diet also failed to show chemopreventive activity against the carcinogen N-methyl-N-nitrosourea; however, when administered at the same dose in the Teklad 4% rodent diet, genistein exhibited significant chemopreventive activity (44–61%). These results demonstrate that GSE is chemopreventive in an animal model of breast cancer; moreover, the diet dependency of the chemopreventive activity for both GSE and genistein suggests that whether or not a compound is chemopreventive may depend on the diet in which the agent is administered.

27 November 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ATAlan T. Tang
Alan T. Tang
KSKatie R. Sullivan
Katie R. Sullivan
CHCourtney C. Hong
Courtney C. Hong
LGLauren M. Goddard
Lauren M. Goddard
AMAparna Mahadevan
Aparna Mahadevan
MKMark L. Kahn
Mark L. Kahn
Cerebral cavernous malformation (CCM) is a genetic, cerebrovascular disease. Familial CCM is caused by genetic mutations in KRIT1, CCM2, or PDCD10. Disease onset is earlier and more severe in individuals with PDCD10 mutations. Recent studies have shown that lesions arise from excess mitogen-activated protein kinase kinase kinase 3 (MEKK3) signaling downstream of Toll-like receptor 4 (TLR4) stimulation by lipopolysaccharide derived from the gut microbiome. These findings suggest a gut-brain CCM disease axis but fail to define it or explain the poor prognosis of patients with PDCD10 mutations. Here, we demonstrate that the gut barrier is a primary determinant of CCM disease course, independent of microbiome configuration, that explains the increased severity of CCM disease associated with PDCD10 deficiency. Chemical disruption of the gut barrier with dextran sulfate sodium augments CCM formation in a mouse model, as does genetic loss of Pdcd10, but not Krit1, in gut epithelial cells. Loss of gut epithelial Pdcd10 results in disruption of the colonic mucosal barrier. Accordingly, loss of Mucin-2 or exposure to dietary emulsifiers that reduce the mucus barrier increases CCM burden analogous to loss of Pdcd10 in the gut epithelium. Last, we show that treatment with dexamethasone potently inhibits CCM formation in mice because of the combined effect of action at both brain endothelial cells and gut epithelial cells. These studies define a gut-brain disease axis in an experimental model of CCM in which a single gene is required for two critical components: gut epithelial function and brain endothelial signaling.

27 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSean P Polster
Sean P Polster
ASAnukriti Sharma
Anukriti Sharma
CTCeylan Tanes
Ceylan Tanes
ATAlan T. Tang
Alan T. Tang
PMPatricia Mericko
Patricia Mericko
IAIssam A. Awad
Issam A. Awad
Cavernous angiomas (CA) are common vascular anomalies causing brain hemorrhage. Based on mouse studies, roles of gram-negative bacteria and altered intestinal homeostasis have been implicated in CA pathogenesis, and pilot study had suggested potential microbiome differences between non-CA and CA individuals based on 16S rRNA gene sequencing. We here assess microbiome differences in a larger cohort of human subjects with and without CA, and among subjects with different clinical features, and conduct more definitive microbial analyses using metagenomic shotgun sequencing. Relative abundance of distinct bacterial species in CA patients is shown, consistent with postulated permissive microbiome driving CA lesion genesis via lipopolysaccharide signaling, in humans as in mice. Other microbiome differences are related to CA clinical behavior. Weighted combinations of microbiome signatures and plasma inflammatory biomarkers enhance associations with disease severity and hemorrhage. This is the first demonstration of a sensitive and specific diagnostic microbiome in a human neurovascular disease.

1 January 2000 in BioFactors
Verified
Journal Article
Closed access
PDF file
HKHelen Kim
Helen Kim
HXHongli Xia
Hongli Xia
LLLin Li
Lin Li
JGJohn Gewin
John Gewin